Nav: Home

Penn cell biologist awarded $5.2 million from NIH for lung regeneration research

October 13, 2016

PHILADELPHIA -Penn Medicine researchers, along with colleagues at Cincinnati Children's Hospital and Boston University, have received a $5.2 million, seven-year grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) to study the cellular and molecular mechanisms that promote lung regeneration. The aim of the grant is to develop treatments for children with congenital lung diseases and adults whose lungs have been damaged from smoking, genetic defects, and acute injury.

The Penn-Cincinnati Children's-Boston University research group is one of seven new research hubs that will comprise the new Progenitor Cell Translational Consortium, bringing together multidisciplinary researchers in the heart, lung, blood, and technology fields from different institutions throughout the country. Recipient institutions will receive a total of $40 million over the next seven years. The Consortium's focus will be on translating advances in progenitor cell biology to new treatments for heart, lung, and blood diseases.

The Penn component of the consortium is led by Edward Morrisey, PhD, the Robinette Foundation Professor of Medicine, a professor of Cell and Developmental Biology, and the director of the Penn Center for Pulmonary Biology, in the Perelman School of Medicine. Morrisey is also the scientific director of the Penn Institute for Regenerative Medicine.

"The aim of our consortium is to harness the innate power of stem and progenitor cells in the lung to promote repair and regeneration and target them using emerging techniques for promoting tissue regeneration," Morrisey said. "We will be examining both pediatric and adult populations since many children suffer from chronic lung diseases such as severe asthma and cystic fibrosis. In adults, we are interested in determining whether we can harness the innate ability of the lung to repair and regenerate to treat chronic lung diseases as well as acute injury." The Penn group will also explore whether new advances in gene editing can be used to treat postnatal lung diseases.

One of the major progenitor cell types that will be targeted by the Penn group is called the alveolar type 2 (AT2) cell. AT2 cells, along with AT1 cells, line the alveoli of the lungs. Alveoli are the tiny air-filled sacs, arranged in clusters in the lungs, in which the exchange of oxygen and carbon dioxide takes place. AT2 cells are responsible for generating pulmonary surfactant, a mixture of proteins and lipids that is necessary for allowing lungs to expand and deflate during every breath as well as fight lung infections. When functioning normally, AT2 cells divide to replace old or damaged lung cells including AT1 cells, maintaining lung health. However, AT2 cell injury can lead to defective regeneration and other diseases including lung cancer and lung fibrosis.

The Penn consortium will work to characterize AT2 cells at multiple levels from mouse and human lungs, seeking to better understand their role in lung function and repair. This information will be used to determine whether AT2 cells can be targeted using gene editing techniques to alter their regenerative potential or correct disease-causing mutations.

The project will concentrate on the role of the ABCA3 gene in AT2 cell biology, mutations in which can cause severe acute and chronic pulmonary disorders in infants and children. ABCA3 mutations account for up to 50 percent of cases of full-term infants with congenital lung disease who are resistant to conventional therapies. At present, there are no proven effective therapies for ABCA3 deficiency other than lung transplantation.

"Using disease-inducing ABCA3 mutations as a paradigm for congenital lung disease, we will target AT2 cells to correct these mutations as well as attempt to promote lung regeneration," Morrisey said. "Ultimately, we hope to use lung stem and progenitor cells for treatment of various forms of lung disease."

The Consortium is funded by the National Heart, Lung, and Blood Institute (U01-HL134745).

University of Pennsylvania School of Medicine

Related Lung Disease Articles:

New hope for patients with severe lung disease
Patients suffering from severe lung disease could see their lives transformed thanks to a 'game-changing' clinical trial carried out by UK experts and led by the team from the Lane Fox Respiratory Service based at Guy's and St Thomas' in London.
Some lung cancer patients benefit from immunotherapy even after disease progression
Some advanced lung cancer patients benefit from immunotherapy even after the disease has progressed as evaluated by standard criteria, according to research presented at the European Lung Cancer Conference (ELCC).
New gene linked to inherited lung disease via disrupted telomerase
Johns Hopkins researchers say they have identified a new disease gene that, when mutated, appears to increase the risk in a small number of people of developing emphysema and a lung-scarring condition known as pulmonary fibrosis.
Research to improve treatment for millions of lung disease patients
New lung scanning technology developed at Monash University has the potential to transform treatment for millions of people with lung disease in Australia and around the world.
Discovery of infants' airway microbiomes may help predict lung disease
In contrast to the general belief that the airways of an infant are sterile until after birth, researchers have found that the infant airway is already colonized with bacteria when a baby is born -- and this is true for infants born as early as 24 weeks gestation.
Baby's breath: A new way to study neonatal lung disease
Investigators at the Saban Research Institute of Children's Hospital Los Angeles have created a novel model for studying a lung disorder of newborn babies.
The lung epithelium in health and disease
This SRC presents emerging areas of scientific interest in lung epithelial biology in development, homeostasis, and disease.
Lung disease: Higher mortality during heat waves
Heat waves are becoming more common in summer and have health-related consequences.
New biomarkers for improved treatment of severe heart and lung disease
New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary arterial hypertension.
A mouse model offers new insights into a rare lung disease
New research from an investigative team at the University of Cincinnati has identified biomarkers and potential therapeutic approaches that may unlock the key to treating pulmonary alveolar microlithiasis, a rare lung disease.

Related Lung Disease Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...